非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析*

doi:10.3969/j.issn.1672-5069.2022.04.017

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (4): 521-525.doi: 10.3969/j.issn.1672-5069.2022.04.017

非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析^*

张文彦, 刘芳, 刘梦露, 陈德喜, 张晶, 时红波, 于海滨

100069 北京市首都医科大学附属北京佑安医院国家临床药物试验机构(张文彦,刘梦露,于海滨);北京市肝病研究所(张文彦,刘芳,时红波,陈德喜);肝病三科(张晶);北京市肝炎和肝癌精准医学与转化工程技术研究中心(时红波,陈德喜)

收稿日期:2021-10-20 出版日期:2022-07-10 发布日期:2022-07-14
通讯作者: 于海滨,E-mail:dryuhaibin@ccmu.edu.cn
作者简介:张文彦,女,33岁硕士研究生。E-mail:zhangwenyan@ccmu.edu.cn
共同第一作者:刘芳,女,36岁,副主任技师。E-mail:907423117@qq.com
基金资助:
^*中国肝炎防治基金会王宝恩肝纤维化研究基金资助项目(编号:2020033);中国肝炎预防控制基金会基金资助项目(编号:TQGB20190050);北京市属医学科研院所公益发展改革试点项目(编号:京医研2019-6)

Plasma exosome differential proteins in patients with non-alcoholic fatty liver diseases

Zhang Wenyan, Liu Fang, Liu Menglu, et al

State Clinical Drug Trial Institution, You’an Hospital Affiliated to Capital Medical University, Beijing 100069, China

Received:2021-10-20 Online:2022-07-10 Published:2022-07-14

摘要/Abstract

摘要： 目的筛选非酒精性脂肪性肝病(NAFLD)患者血浆外泌体差异蛋白,分析其功能及其生物学过程,为NAFLD患者临床诊断提供参考依据。方法 2020年7月～10月我院诊治的NAFLD患者3例和健康体检者3例,采用串联质谱标签(TMT)标记定量蛋白质组学技术对血浆外泌体蛋白进行鉴定和定量分析,筛选差异蛋白并进行功能富集分析,了解其参与的生物学过程。结果经外泌体蛋白质组学分析,共鉴定出蛋白质387种,以倍数上调＞1.2倍或下调＞1.2倍,且P＜0.05为标准筛选出差异表达蛋白34种;健康人比,NAFLD患者上调蛋白25种,下调蛋白9种;生物信息学分析结果显示,这些蛋白主要参与了脂质的储存和代谢、免疫反应、纤维素形成等生物学过程,并与胰岛素抵抗、炎症反应、细胞损伤等信号通路密切相关。结论采用TMT标记定量蛋白质组学技术筛选NAFLD患者差异蛋白可能为其诊治提供指引。

关键词: 非酒精性脂肪性肝病, 外泌体, 差异蛋白, 蛋白质组学

Abstract: Objective The aim of this study was to screen plasma exosome differential proteins in patients with non-alcoholic fatty liver diseases (NAFLD) and analyze their roles in biological processes. Methods Three patients with NAFLD and three healthy individuals were encountered in You'an Hospital, Capital Medical University between July and October 2020. The plasma exosome proteins were identified and quantitatively characterized by tandem mass tag (TMT) labeled quantitative proteomics. The differential proteins and their functional enrichment were screened, and the biological processes involved were analyzed. Results A total of 387 proteins were identified by exosome proteomic analysis, and out of them, 34 differentially expressed proteins were screened out according to the criteria of up-regulation > 1.2 folds or down-regulation > 1.2 folds and P<0.05; 25 up-regulation proteins and 9 down-regulation proteins were found in patients with NAFLD compared with healthy persons; the bioinformatics analysis showed that these proteins were mainly involved in lipid storage and metabolism, immune response, cellulose formation and other biological processes, and were closely related to insulin resistance, inflammatory response, cell damage and other signaling pathways. Conclusion The differential proteins screened by TMT marker quantitative proteomics might be used as serological markers for the study of NAFLD.

Key words: Nonalcoholic fatty liver disease, Exosome, Differential protein, Proteomics

张文彦, 刘芳, 刘梦露, 陈德喜, 张晶, 时红波, 于海滨. 非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 521-525.

Zhang Wenyan, Liu Fang, Liu Menglu, et al. Plasma exosome differential proteins in patients with non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(4): 521-525.

参考文献

[1] McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol,2015,62(5):1148-1155.
[2] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018,15(1):11-20.
[3] Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res,2014,24(6):766-769.
[4] Farooqi AA, Desai NN, Qureshi MZ, et al. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol Adv,2018,36(1):328-334.
[5] Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol,2007,9(6):654-659.
[6] Kornek M, Lynch M, Mehta SH, et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology,2012,143(2): 448-458.
[7] Hirsova P, Ibrahim SH, Verma VK, et al. Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology,2016,64(6): 2219-2233.
[8] Tyanova S, Temu T, Sinitcyn P, et al. The perseus computational platform for comprehensive analysis of (prote)omics data. Nature Methods,2016,13(9): 731-740.
[9] Geis-Asteggiante L, Belew AT, Clements VK, et al. Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. J Proteome Res,2018,17(1):486-498.
[10] Tkach M, Thery C. Communication by extracellular vesicles: Where we are and where we need to go. Cell,2016,164(6):1226-1232.
[11] Keerthikumar S, Chisanga D, Ariyaratne D, et al. ExoCarta: A web-based compendium of exosomal cargo. J Mol Biol,2016,428(4):688-692.
[12] Eguchi T, Sogawa C, Okusha Y, et al. Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. PLOS One,2018,13(2):e191109.
[13] Rosa-Fernandes L, Rocha VB, Carregari VC, et al. A perspective on extracellular vesicles proteomics. Front Chem,2017,5:102.
[14] Sinha A, Principe S, Alfaro J, et al. Proteomic profiling of secreted proteins, exosomes, and microvesicles in cell culture conditioned media. Methods Mol Biol,2017,1722:91-102.
[15] Atay S, Wilkey DW, Milhem M, et al. Insights into the proteome of gastrointestinal stromal tumors-derived exosomes reveals new potential diagnostic biomarkers. Mol Cell Proteomics,2018,17(3):495-515.
[16] Intasqui P, Bertolla RP, Sadi MV. Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics,2018,15(1): 65-79.
[17] Wolf G. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev,2007,65(5):251-256.
[18] Nobili V, Alkhouri N, Alisi A, et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol,2009,7(5):575-579.
[19] Tan Y, Sun LQ, Kamal MA, et al. Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. Biochim Biophys Acta,2011,1811(12): 1045-1053.
[20] Seiffert D, Keeton M, Eguchi Y, et al. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA,1991,88(21):9402-9406.

非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析^*

Plasma exosome differential proteins in patients with non-alcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王晴, 张利莉. 当2型糖尿病遇上非酒精性脂肪性肝病:1+1＞2 ？[J]. 实用肝脏病杂志, 2022, 25(4): 460-463.
[2]	汪晓燕, 钟雪玉, 吴春燕. 沙格列汀干预非酒精性脂肪性肝病合并2型糖尿病大鼠肝组织AMPK/mTOR-TFEB自噬信号通路蛋白表达变化^*[J]. 实用肝脏病杂志, 2022, 25(4): 476-479.
[3]	李亚文, 周军. 化痰祛湿疏肝方联合辛伐他汀治疗非酒精性脂肪性肝病痰湿内阻证患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 526-529.
[4]	年福临, 鲁晓岚. 糖尿病与非酒精性脂肪性肝病^*[J]. 实用肝脏病杂志, 2022, 25(3): 314-317.
[5]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[6]	蔡冬梅, 吴文娟, 姜亦伦, 居敏昊. CT检测非酒精性脂肪性肝病合并高危冠状动脉斑块患者冠状动脉指标临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 383-386.
[7]	周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 157-160.
[8]	侯文靖, 吴广明, 盖慧慧. 三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 174-178.
[9]	陈凯, 居峰. 多烯磷脂酰胆碱联合扶正化瘀片治疗非酒精性脂肪性肝病患者肝脏超声脂肪变性评分变化^*[J]. 实用肝脏病杂志, 2022, 25(2): 219-222.
[10]	梁烨倍, 杨春光, 王昆凤, 胡秋明, 李妍辉, 罗琴, 陈浩, 郑亚雄, 余俊, 唐小英, 史华祥, 牛涛, 吴伟, 侯旭宏, 贾伟平. 云南省布朗族成人非酒精性脂肪性肝病流行特点研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 223-226.
[11]	李伟, 黄宇, 钟璟, 韦隽. 外周血PNPLA3 rs738409基因多态性与非酒精性脂肪性肝病遗传易感性研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 227-230.
[12]	莫超艳, 杨有强, 钟嫄, 肖友雪. 非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 231-234.
[13]	王芳, 高晓霞, 汪庆强. 黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 235-238.
[14]	黄蝶, 田昊宇, 李异玲. 非酒精性脂肪性肝病血清标志物研究进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 297-300.
[15]	吕春卉, 李大炜, 王小洁, 康晓平, 韩宗晟, 朱允. 二甲双胍联合辛伐他汀治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(1): 50-53.